Full text is available at the source.
Abstract
Use of glucagon-like peptide-1 (GLP-1) receptor agonists among US adults with diabetes is examined in relation to cancer history.
- The study focuses on adults diagnosed with diabetes, both those who have a history of cancer and those who do not.
- Variations in the usage patterns of GLP-1 receptor agonists are assessed in this population.
- Findings may reveal differences in treatment choices based on cancer history.
Simplified